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ABSTRACT

A pharmaceutical composition of canavanine, and a method
treatment of cancer, particularly pancreatic cancer with
L-canavanine is disclosed.

7 Claims, 5 Drawing Sheets

US. Patent

Sep. 3, 1996

Sheet 1 of 5

5,552,440

US. Patent

Sep. 3, 1996

Sheet 2 of 5

5,552,440

(TPRDEAIMYOSNDT)

(PTRDEAIYMOSND)T

TUMOR VOLUME (mm3)1l1lT3

3?gure

2Figure

US. Patent

SE8“5:.32?

Sep. 3, 1996

654321

D a V: 0

Day‘!

Sheet 5 of 5

Day14

5,552,440

M21

M28

M21

M28

TIME (day)

Figure 6A

Day?

M14
TIME (day)

Figure 6B

5,552,440
1

2

USE OF L-CANAVANINE AS A
CHEMOTHERAPEUTIC AGENT FOR THE
TREATMENT OF PANCREATIC CANCER

biliary tract (13) and/or percutaneous placement of bypass
conduits (l4).

Aggressive multimodality therapy combining chemo
therapy and radiation therapy which surgery has been the
response of choice when surgery alone was not elfective.

TECHNICAL FIELD

Radiation has been the cornerstone of therapy for unrespect

The invention relates to a pharmaceutical composition

able cancer of the pancreas and 5-?uorouracil (S-FU) che
motherapy has been for an important adduct to radiation

comprising canavanine, and a method treatment of cancer,

particularly pancreatic cancer, with L-canavanine.
10

BACKGROUND

More than 26,000 people die each year in our country
from pancreatic adenocarcinoma (1, see numbered refer

treatment in these patients (15). However, despite these
valiant elforts, no patient survives ?ve years.
A single, small randomized trial showed signi?cant ben
e?t from combined radiation and chemotherapy given two
years after operation (16). While this study was limited by

ences below). Death is the inevitable consequence to more

an inadequate number of patients, none the less there was

than 90% of patients with this disease. It is the fourth most

bene?t to patients receiving rnulti-modality treatment.

common cause of cancer death in men and the ?fth most

Effective radiotherapy needs to maximize exposure of the

common for women (2). Overall, it is the fourth most

affected tissues while sparing normal surrounding tissues.
Interstitial therapy, where needles containing a radioactive

common carcinoma after those of the lung, colon and breast
(3). The incidence of this disease is linear with age to sixty 20 source are embedded in the tumor, has become a valuable
but its occurrence increases markedly in the seventh or
new approach. In this way, large doses of irradiation can be
eighth decade of life (4). There are several different histolo
delivered locally while sparing the surrounding normal
gies associated with cancer of the pancreas including small
structures (17). Intraoperative radiotherapy, where the beam
cell cancer, cystadenocarcinoma, islet cell tumors, lym
is placed directly onto the tumor during surgery while
phoma and carcinoid; however, 75-80% of the cases involve
normal structures are moved safely away from the beam, is

adenocarcinomas of ductal origin (5). The only de?nitive
risk factor in pancreatic cancer is cigarette smoking. A

another specialized radiation technique. Again, this achieves
e?’ective irradiation of the tumor while limiting exposure to
surrounding structures. Despite the obvious advantage of

typical smoker accepts up to four times the risk of a

nonsmoker (6).
Located in the upper abdomen in the retroperitoneum, the
pancreas is associated intimately with many major structures

30

approaches predicated upon local control of the irradiation,
patient survival is not signi?cantly improved (18, 19).
The foundation of chemotherapy for carcinoma for the
pancreas has employed 5-FU(20). Here too, the prognosis is
bleak; no better than 10-15% of patients treated with 5-FU

including the portal vein, stomach, duodenum, common bile
duct and the superior mesenteric artery. As the tumor grows,
the patient’s symptoms result from tumor in?ltration of

weight loss and jaundice. The latter condition presents

will experience a signi?cant reduction in tumor size; overall
survival rates are not improved. The addition of other
chemotherapeutic agents such as cis~platin or adriarnycin

symptoms in no more than one half of the patients. Once
tumor in?ltration occurs other structures such as the portal

has not dramatically improved disease management (20).
For this reason, attempts to augment the intrinsic activity of

surrounding structure causing pain, nausea, vomiting,

35

vein become affected and this precludes curative resection~

ing of the pancreas.

S-FU have been undertaken. On one approach, 5-FU is
40

Effective treatment of pancreas cancer must achieve two

converted to 4-?uorodeoxyuridine monophosphate
(FdUMP) which binds covalently to thyrnidylate synthase
(EC 2.1.1.45). This competitive inhibitor disrupts DNA

dillicult goals: control of the primary tumor mass, both
replication by curtailing deoxyuridine monophosphate
initially and subsequently, and treatment of the metastatic
anabolism to deoxythyrnidine.
tumor cells. As a result of its insidious onset, the diagnosis
Reduced folates such as leucovorin are a necessary cofac
of pancreas cancer is delayed frequently for several months. 45
tor for FdUMP binding to thymidylate synthase (21). Cancer
This delay has profound implications, since metastatic
cells depauperate in reduced folate are resistant to S-FU
spread to the liver or lymph nodes has been observed at a
chemotherapy but that resistance can be circumvented by
time of diagnosis in 60% of patients, and this factor dimin
providing exogenous reduced folate (22). While 5-PU plus
ishes the prospect for long—term survival (7). Also, there are
no known speci?c markers of carcinoma of the pancreas and 50 leucovorin relative to 5-FU alone has proven e?icacious in
treating colon cancer, patients with pancreas cancer received
it is asymptomatic in its early stage (8).
no bene?t by providing these two drugs in combination (23).
Conventional Therapy for Pancreatic Cancer

Currently, surgery is the primary and only curative

S-Fluorouracil can also be converted to S-?uorouridine

therapy for pancreas cancer. However, only 15-25% of

monophosphate which can be incorporated into mRNA

tumors are resectable at the time of diagnosis (9) and 55

thereby a?ecting protein translation. N-N-(phosphonacetyly

regrettably only 10-20% of patients resected will survive

L-aspartic acid (PALA) inhibits the transformation of aspar
tic acid to orotidine monophosphate which is converted

more than two years (10). With these less tan satisfactory

surgical results, present day therapy has evolved in two
directions: palliation of symptoms and aggressive multimo
dality treatment regime’s which combines surgery with
chemotherapy and radiation treatment.
Palliative therapy has become a major thrust of current

60

subsequently to uridine monophosphate. The use of PALA
provides a means of depleting essential uridine monophos~
phate. In the absence of uridine monophosphate, ?uorouri

dine monophosphate is incorporated preferentially into
mRNA which promotes cell death. Preliminary data from

treatment. Initial relief of symptoms has relied on surgery

experiments employing high dose (2,600 mg/m2) 5-FU after

with surgical bypass of gastric outlet obstruction (11) and

operative bypass of biliary obstruction (12). Subsequent

pretreatment with PALA have been promising as signi?cant
tumor reduction has been noted in 5 of 6 patients (24).

symptomatic treatment has centered around endoscopic
placement of biliary stents to bypass tumors blocking the

However, subsequent phase II data have been less positive
(25) with only one patient in 29 achieving any bene?t.

5,552,440
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While new experimental efforts in treating pancreas can
cer have been initiated, their limited success emphasizes the

FIG. 6A and 6B show Mice tumor volume (cm3) of
control mice (A) and canavanine-treated mice (B). Canava

need for radically new approaches in the management of this
devastating disease. The present invention provides an addi

nine-treated animals were injected daily with 4 g/Kg of drug
in sterile saline, control animals receive 0.9% (w/v) NaCl.

tional alternative for the treatment of cancers, particularly
pancreatic cancer by providing for a pharmaceutical com
position comprising canavanine, and a method treatment of
cancer, particularly pancreatic cancer with canavanine.

DESCRIPTION OF THE INVENTION

The invention provides a pharmaceutical composition
comprising canavanine, and a method treatment of cancer,

DISCLOSURE OF THE INVENTION

particularly pancreatic cancer with canavanine. A depiction

The present invention provides a method of treating
pancreatic cancer by administering a pharrnaceutically
effective amount of a composition comprising L-canavanine
to a patient with pancreatic cancer.

of the canavanine molecule appears below.
In addition to the amino acids which are the building

blocks of proteins, living systems also produce about 750
15

The invention also provides a pharmaceutical composi
tion comprising a pharrnaceutically effective amount of a

composition comprising L~canavanine.
In an alternative embodiment the invention provides

pharmaceutical composition comprising canavanine and

20

against a wide array of insects and other pests (28, 29).
Biochemical Basis for Canavanine’s Antimetabolic Proper

In still another embodiment the invention provides a

pharmaceutical composition comprising canavanine and a
compound selected from the group consisting of (S)-2
25

lenomethionine, L-3-[N-hydroxy-4-oxypyridyl]-2-arnino
propionic acid and mixtures thereof.
The above and other objects of the invention will become
readily apparent to those of skill in the relevant art from the

following detailed description and ?gures, wherein only the

arginyl-tRNA synthetase. This canavanine-sensitive insect
30

Vitellin, an essential egg protein, is constructed by the

[Orthoplera] from amino acids released by degradation of
Vitellogenin (31). Administration of canavanine to the
female locust produces a canavanyl Vitellogenin in which 18
of the nearly 200 arginine residues are replaced by canava

invention is capable of modi?cations within the skill of the
relevant art without departing from the spirit and scope of
the invention.

nine (31); thus, canavanine occurs about once every 225

amino acids. In spite of this paucity in canavanine content,
it elicits a profound alteration in‘vitellogenin structure best

BRIEF DESCRIPTION OF DRAWINGS
40

elsewhere.
FIG. 2 shows tumor growth in male Fischer rats following

into this protein (31).
In response to microbial infection or mechanical injury,

administration of canavanine, 2.0 (closed rectangle) or 3.0

larvae of the meat-eating ?y, Phormia terranovae, generate

(closed circle) g/kg for 9 days. Control animals (closed

a group of antibacterial proteins known trivially as the
diptericins. If canavanine is included at the time of mechani

triangle) receive 0.95 received 0.95 (w/v) NaCl. The stan
dard error bar was omitted if within the area occupied by the

cal injury, it is incorporated into newly produced diptericins
(32). Analysis of the diptericin activity of arginine- or

data point, n=5 S.E.M.
FIG. 3 shows tumor growth in male Fischer rats following

canavanine-treated larvae reveals a nearly total loss of

5 daily so injections of 35 mg/kg S-FU (closed circle) 2.0

detectable biological activity for 3 of the 4 protective

proteins-only diptericin A displays biological activity. Thus,
canavanine incorporation into these protective proteins in
55

occupied by the data point, n:5 S.E.M.

represents the means from an experiments. The standard
error bar was omitted when it fell within the area occupied

by the data point.

place of arginine curtails severely their biological activity.
Manduca sexta larvae respond to injected fragments of
the cell wall of Micrococcus lutea by producing lysozyme
(EC 3.2.1.17), a protein which cleaves the mucopolysaccha

(w/v) NaCl. The S.E. bar was omitted if it fell within the area

modi?ed media containing 0.4 mM arginine. Each point

observed by electrophoretic analysis (FIG. 1).
Other chemical, physical, biochemical, and immunologi
cal tests con?rm the dramatic change in the three dimen
sional conformation resulting from canavanine assimilation

by gradient polyacrylarnide electrophoresis as described

FIG. 4 shows MIA-PaCa-l cells were exposed to the
indicated level of canavanine for 3 days in Dulbecco’s

hemolymph and body wall (30).

gravid migratory locust, Locusta migratoria migratorioides

described, simply by way of illustration of the best mode of
carrying out the invention. As is readily recognized the

g/kg canavanine (closed square), 1.0 g/kg canavanine (open
triangle), 35 mg kg 5-FU plus 2.0 g/kg canavanine (open
circle) or 35 mg/kg 5-FU plus 1.0 g/kg canavanine (open
square). Control animals (closed triangle) received 0.95

ties
Studies with larvae of the tobacco horn worm, Manduca
sexta, reveal that canavanine is an effective substrate for

replaces on average at least one of three arginyl residues
with canavanine in the de novo synthesized proteins of the

preferred embodiments of the invention are shown and

FIG. 1 shows electrophoretic evidence of structural
change caused by canavanine. Vitellogenin was examined

tural analog of L-arginine, is such a higher plant toxicant.
Produced and stored by leguminous plants, canavanine is
part of their chemical defense, where it functions as a barrier

5-?uorouracil.

aminoethyl-L-cysteine, L-2-azetidine carboxylic acid, L-se

nonprotein amino acids (26). These compounds possess a
rich structural diversity and often elicit deleterious biologi
cal effects in viruses and all living systems (27), L-Cana
vanine, the L-2-amino-4-(guanidinoxy) butyric acid struc

ride framework of the cell wall. Administration of 1 mg
60

canavanine g-1 fresh larval weight at the time of bacterial
challenge generates canavanyl lysozyme with a ratio of
canavanine to arginine of l:3.8i0.2(33). Canavanyl
lysozyme exhibits a 50% loss of catalytic activity (33).

These insectan studies support out contention that the anti
FIG. 5 shows MIA~PaCa~1 cells were exposed to various 65 metabolic etfects of canavanine re?ects its incorporation
amounts of canavanine with the indicated level of arginine
into newly synthesized proteins which alters essential con
to generate this family of curves.
formation and produces dysfunctional proteins.

5,552,440
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Canavanine’s Efficacy against Pancreatic Tumor

Canavanine may be produced by isolated the amino acid

Analysis of L-[guanidinoxy-MC] canavanine uptake into

from jack beans by the method of Kitagawa, Tokiyama, J.
Biochem., (Tokyo) 11, 265 (1929) incorporated herein by

the protein of the major organs of the rat disclosed the

highest radiolabeling in pancreatic proteins (36). These

reference in its entirety. See also Nyberg et al., J. Am. Chem.
Soc., 79, 1222 (1957); Frankel et al., J. Am Chem. Soc.,

proteins had 10 times the amount found in liver, muscle or

brain samples. The ef?cient incorporation of radiolabeled
canavanine into pancreatic proteins coupled with its dem
onstrated ability to create dysfunctional proteins prompted

3127 (1963); and Yamada et al., Agr., Biol. Chem., 37, 2201
(1973) for additional methods of synthesis of canavanine,
also incorporated herein by reference.
Evaluation of Canavanine’s Antineoplastic Activity
Canavanine‘s ability to disrupt the growth of rapidly

evaluation not only of canavanine but more importantly its
derivatives as chemotherapeutic agents for human pancreas
cancer.

dividing and growing larval cells led to whole animal studies
of its antineoplastic activity. The inventors found that cana

A basic understanding of the biochemical basis for cana

vanine’s antimetabolic properties has emerged over the past
?ve years and these efforts have permitted development of

vanine may be incorporated into key protein(s) unique to the
cancer cell and that these structurally aberrant proteins,
critical to the growth and proliferation of the cancer cell,

a sound rationale for derivative synthesis. Chemical syn

thetic efforts, detailed herein, hold the promise of providing
drugs with markedly enhanced e?‘icacy and permit their

may be dysfunctional.

administration at signi?cantly lower dose levels than those
EXAMPLE 1

required by canavanine. It has been unequivocally estab
lished that a l g kg-1 dose of canavanine has no adverse
effect on body weight nor on other discernible parameters of

Employing a solid rat colonic carcinoma in Fischer F433
rats, it was demonstrated that canavanine possesses appre

the rat.

ciable antineoplastic activity. For example, administration of
canavanine at a 3.0 g/kg dosing regimen for 5 consecutive
days results in a 22% loss in tumor volume, while 9 days of
daily dosing elicits a 60% diminution of the tumor (34).
However, canavanine’s is cumulatively toxic and can
result in a weight loss of 19% in animals dosed with 3.0 g/kg

A chemotherapeutic strategy predicated upon controlling
cancer cell growth through the formation of structurally

aberrant, dysfunctional proteins has been developed. Such
25

macromolecules deny the cancer cell essential metabolites,
undermine regulatory and other cellular control elements

and pervasively disrupt critical cellular growth-related pro
cesses. Current treatment practices have not enjoyed sub
stantial success and a radical new approach is justi?ed. The
approach of the invention is one with a strong biochemical
foundation that provides a sound rationale for the develop

canavanine for 5 days (34). Additional experimentation
established unequivocally that the observed body weight
loss is not responsible for canavanine’s antitumor e?ects

(34).

ment of new derivatives for use as chemotherapeutic agents.

Most importantly, canavanine’s mode of actions is snot

EXAMPLE 2

directed at DNA replication, events that occur prior to
Initial experimental efforts have been extended to deter
transcription of the message, nor at message translation.
The present strategy for developing an effective chemo
mine if canavanine’s e?icacy as an anticancer agent is 35
therapeutic agent does not focus on nucleic acid metabolism
increased in combination with S-?uorouracil (S-FU). Pro~
but rather at the level of protein function.
viding canavanine at 1.0 g/kg or 2.0 g/kg daily for 5

Evaluation of Drug Ef?cacy

consecutive days with 5-FU increases signi?cantly the anti

tumor activity of either drug alone (see FIG. 2). Body weight
loss experienced by canavanine-treated animals increases in

A number of cell lines derived from pancreatic ductal
40

those animals given both drugs. These studies evidence that
combination therapy o?fers a viable means of improving

canavanine’s intrinsic efficacy.

adenocarcinoma have been established, including CFPAC-l
(ATCC CRL 1918), PANC-l (ATCC CRL 1469), MIA
PaCa- 1, and MIA-PaCa-2 (ATCC CRL 1420). MIA-PaCa2
is highly tumorigenic, has lost the ability to be growth
regulated, and is derived from metastatic cells. CFPAC- 1,

In order to improve canavanine’s potential as a chemo
which is derived from a primary tumor line, is the faster
therapeutic agent, a number of canavanine derivatives were 45 growing cell line and is preferable for whole animal studies.
evaluated for enhanced antitumor ef?cacy and diminished
The availability of each of these lines from the American

growth-inhibiting activity.

Type Culture Collection, 12301 Parklawn Drive, Rockville,

Enzyme activity studies conducted, reveal a number of
other nonprotein amino acids whose assimilation into pro

Md., U.S.A., insures an effective means for initial screening
of newly synthesized derivatives both alone and in combi
nation with other developed compounds as well as with

teins disrupts normal catalytic activity. Some natural prod

drugs employed presently inhuman chemotherapy. The most

ucts such a (S)~2—aminoethyl-L-cysteine, L~2~azetidine car

promising candidates are employed in whole animal evalu

boxylic acid, L~selenomethionine, and L-3-[N~hydroxy-4

ation involving nude mice.
oxypyridyl]-2- aminopropionic acid or mixtures thereof are
This invention permits an effective transition from labo
not only very active but also interact with canavanine to 55
ratory ?ndings and evaluations to their bene?cial employ
signi?cantly amplify canavanine-mediated disruption of
ment in alleviating the human suffering associated with this
protein function (35).
dreadful disease.
Thus, there are a number of nonprotein amino acids
EXAMPLE 3
beside canavanine able to substitute for their protein amino

acid counterpart to generate dysfunctional proteins. These
natural products often possess signi?cant antitumor poten~

60

tial alone, in combination with canavanine, and with other

therapeutic drugs.
The ability to assault the local cancer cell and even its
metastatic offspring simultaneously with an array of non
protein amino acid derivatives o?ers a weapon of consid

erable potential value.

65

Antitumor Effect of Canavanine in the Male Fischer Rat
The marked antitumor effect of L-canavanine was dem
onstrated initially by our research group in studies on a solid,
colonic carcinoma in male Fischer 344 rats. Administration

of 3 g/kg canavanine sc reproducibly prevented tumor
growth during 5 or 9 consecutive treatment days. In fact, the
?nal fresh tumor weight was typically 10% less than the

weight of the initial tumor (34) (FIG. 2).

5,552,440
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To enhance canavanine’s antineoplastic activity, it was
tested in combination with 5-FU (FIG. 3). Providing cana
vanine at 1.0 g/kg or 2.0 g/kg daily for 5 consecutive days
with 5-FU increased signi?cantly the antitumor activity of
either drug alone. This whole animal study was of consid
erable importance because it demonstrated that combination

capsule having the appropriate size. If soft capsules are
desired a slurry of the compound with an acceptable veg
etable, light petroleum, or other inert oil can be encapsulated

by machine into a gelatin capsule.
Suspensions, syrups and elixirs may be used for oral

administration of ?uid unit dosage forms. A ?uid preparation
including oil may be used for oil soluble forms. A vegetable

therapy offers a viable mean of improving canavanine’s
intrinsic e?icacy and supports our contention that canava

oil such as corn oil, peanut oil or safflower oil, for example,

together with ?avoring agents, sweeteners and any preser
vatives produces an acceptable ?uid preparation. A surfac

nine and its derivatives in conjunction with S-FU may offer
an effective chemotherapeutic strategy. Alternatively, cana
vanine therapy may be combined with radiotherapy.

tant may be added to water to form a syrup for ?uid unit

dosages. Hydro-alcoholic pharmaceutical preparations may
EXAMPLE 4

be used having an acceptable sweetener such as sugar,
saccharine or a biological sweetener and a ?avoring agent in
the form of an elixir.

The Effect of Canavanine on MIA~PaCa~I Cells.
Work has been performed to evaluate the e?ect of cana
vanine on MIA-PaCa-l cells. Cell survival was determined

Pharmaceutical compositions for parenteral administra
tion can also be obtained using techniques standard in the art
as set forth in Remington ’s Pharmaceutical Sciences, 18th

by the ability of viable cells grown on Dulbecco’s modi?ed
medium to reduce tetrazolium dye to a colored forrnazan

Ed., 1989, Mack Publishing Company, incorporated herein

product. The experiment depicted in FIG. 4 discloses dra
matically the potent e?icacy of canavanine against these

by reference it its entirety.
Accordingly, compositions suitable for administration are
particularly included within the invention. Parenteral solu~

cells.
That the antitumor potential of canavanine is related

tions or suspensions may be administered. If desired, a more

directly to the competing arginine concentration is depicted
in FIG. 5. This ?nding is of great importance because it

concentrated slow release form may be administered.

Accordingly, incorporation of the active compounds in a
slow release matrix may be implemented for administering
transderrnally. The compounds may preferably be adminis

reveals that canavanine is functioning as an effective argi
nine antagonist. This point is seminal to our contention that
the antitumor e?ect of canavanine is related to its compe

tered at about 1 to 20% of the composition and more

tition with arginine for arginyl-tRNA synthetase.

preferably about 5 to 15% wt % of the active ingredient in
the vehicle or carrier.

EXAMPLE 5

The Antineoplastic E?'ect of Canavanine in the Nude Mouse
Experimental effects with athymic nude mice were con
ducted with 6 treated and control mice. The palpable
CFPAC-l-derived tumors grew slowly but after 28 days 35

appreciable tumor growth had occurred in all experimental
animals (FIG. 6A). By contrast, the CPFAC-l-derived
tumors exhibited little growth in canavaninetreated animals
(FIG. 6B). In 2 of the 7 experimental animals, a precipitous
decline in tumor volume was observed during the ?rst
treatment week. These exciting experimental results add
further support to the fact that canavanine and its derivatives
possess considerable potential for the treatment of human

40

The above and other drugs can be present in the reservoir
alone or in combination form with pharmaceutical carriers.

The pharmaceutical carriers acceptable for the purpose of
this invention are the art known carriers that do not

adversely aifect the drug, the host, or the material compris
ing the drug delivery device. Suitable pharmaceutical car
riers include sterile water; saline, dextrose; dextrose in water
or saline; condensation products of castor oil and ethylene
oxide combining about 30 to about 35 moles of ethylene
oxide per mole of castor oil; liquid acid; lower alkanols; oils
such as corn oil; peanut oil, sesame oil and the like, with
emulsi?ers such as mono- or di-glyceride of a fatty acid, or

a phosphatide, e.g., lecithin, and the like; glycols; polyalky~

pancreatic carcinoma.

lene glycols; aqueous media in the presence of a suspending

Further, the compounds of the present invention are useful 45 agent, for example, sodium carboxymethylcellulose; sodium
alginate; poly(vinylpyrolidone); and the like, alone, or with
to humans and animals in unit dosage forms, such as tablets,
suitable dispensing agents such as lecithin; polyoxyethylene
capsules, pills, powders, granules, suppositories, sterile
stearate; and the like. The carrier may also contain adjuvants

in pharmaceutical compositions for systemic administration

such as preserving stabilizing, wetting, emulsifying agents

parenteral solutions or suspensions, sterile non-parenteral
solutions or suspensions oral solutions or suspensions, oil in
water or water in oil emulsions and the like, containing
suitable quantities of an active ingredient.
For oral administration either solid or ?uid unit dosage
forms can be prepared. The compounds are useful in phar

50

maceutical compositions (wt %) of the active ingredient

55

The effective dosage for mammals may vary due to such
factors as age, weight activity level or condition of the

with a carrier or vehicle in the composition in about 0.01 to

99% and preferably about 5 to 15%.
Either ?uid or solid unit dosage forms can be readily
prepared for oral administration. For example, the com
pounds can be mixed with conventional ingredients such as

dicalciumphosphate, magnesium aluminum silicate, magne
sium stearate, calcium sulfate, starch, talc, lactose, acacia,
methyl cellulose and functionally similar materials as phar

and the like together with the penetration enhancer of this
invention.
subject being treated. Typically, an effective dosage of a
compound according to the present invention is about 0.1 to
50 mg per kilogram of the subject’ 5 weight administered per

day. Preferably about 25 to 50 mg per kilogram body weight
is administered a day. The required dose is less when
administered parenterally, preferably about 25-30 mg per
60

kilogram of body weight per day may be administered

intramuscularly.
The purpose of the above description and examples is to

illustrate some embodiments of the present invention with
maceutical excipients or caniers. A sustained release for
out implying any limitation. It will be apparent to those of
mulation may optionally be used. Capsules may be formu 65 skill in the art that various modi?cations and variations may
lated by mixing the compound with a pharmaceutical diluent
be made to the composition and method of the present
which is inert and inserting this mixture into a hard gelatin
invention without departing from the spirit or scope of the

5,552,440
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invention. All patents and publications cited herein are

28. Rosenthal GA. In: Insecticides: Mechanism of Action
and Resistance D. Otto & B. Weber, eds, Intercept Ltd,

incorporated by reference in their entireties.

Andover, England, 1982.
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